Should I Buy Exact Sciences (EXAS)? Finance YouTuber Analysis

This creator believes Exact Sciences shares could reach $140 by 2027 from around $60 today, driven by continued growth in its core Cologuard and Oncotype tests, which are expected to double revenue to $4 billion, and an additional $1 billion from pipeline products. The company benefits from strong brand recognition, established physician relationships, and a high gross margin that allows for reinvestment and operational leverage, particularly in sales and marketing. They also highlight the company's strong moat due to its established platform and data advantage in cancer diagnostics.

“The headline is that we believe shares of Exact Sciences could expand uh from I believe around sixty dollars a share today to about a hundred and forty dollars per share uh by 2027 in our base case.”

This creator believes the market consensus on Exact Sciences, viewing it solely as a Cologuard play, is incorrect. Their research suggests a much broader potential for the company within the multi-ohmic space, indicating that its true value is being overlooked.

“consensus seems to dismiss exact as nothing but a colaguard play couldn't be further from the truth”

Exact Sciences is added as a unique bet from the ARK Genomic Revolution ETF, which focuses on biotech and information technology disrupting healthcare. It represents a significant holding within the fund.

“from here i'll add exact sciences ticker exas pacific biosciences ticker pacb and vertex pharmaceuticals ticker vrtx”